Needham Reiterates Buy on Ionis Pharmaceuticals, Maintains $60 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Joseph Stringer reiterates a Buy rating on Ionis Pharmaceuticals (NASDAQ:IONS) and maintains a $60 price target.
February 22, 2024 | 10:12 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham analyst Joseph Stringer reiterates a Buy rating on Ionis Pharmaceuticals with a $60 price target.
The reiteration of a Buy rating and maintenance of a $60 price target by a reputable analyst like Joseph Stringer from Needham is likely to instill confidence among investors and could positively influence Ionis Pharmaceuticals' stock price in the short term. Analyst ratings, especially from well-regarded financial institutions, can significantly impact investor sentiment and stock prices.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100